Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Intuvax + Sorafenib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Intuvax||Ilixadencel||Intuvax (ilixadencel) consists of dendritic cells, derived from healthy blood donors, to stimulate the immune system in an anti-tumor response (PMID: 28642820, PMID: 32535637, PMID: 30719425).|
|Sorafenib||Nexavar||BAY 43-9006||CSF1R Inhibitor 24 FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR-beta Inhibitor 13 RAF Inhibitor (Pan) 16 RET Inhibitor 39 VEGFR2 Inhibitor 35||Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||hepatocellular carcinoma||not applicable||Intuvax + Sorafenib||Case Reports/Case Series||Actionable||In a Phase I trial, Intuvax (ilixadencel) alone or in combination with Nexavar (sorafenib) demonstrated safety in hepatocellular carcinoma patients, and resulted in one partial response (Intuvax monotherapy), stable disease in 5 patients, increased circulating tumor-specific CD8-positive T-cells in 82% (9/11) of patients receiving Intuvax alone and 50% (2/4) of patients also receiving Nexavar, median time to progression of 5.5 months, and median overall survival of 7.5 months (PMID: 30719425; NCT01974661).||30719425|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|